---
layout: minimal-medicine
title: Ado-trastuzumab Emtansine
---

# Ado-trastuzumab Emtansine
### Generic Name
Ado-trastuzumab emtansine

### Usage
Ado-trastuzumab emtansine is a targeted cancer therapy used primarily to treat HER2-positive metastatic breast cancer.  This means it's effective against breast cancer cells that overexpress a protein called HER2.  The medication is specifically indicated for patients who have already received treatment with trastuzumab (another HER2-targeted therapy) and a taxane (a type of chemotherapy) either separately or in combination.  It's also used as an adjuvant therapy (treatment given after the primary cancer treatment to reduce the risk of recurrence) for patients with HER2-positive early-stage breast cancer who still have residual invasive disease after neoadjuvant (pre-surgical) treatment with taxanes and trastuzumab.  In simpler terms, it's used for advanced breast cancer that hasn't responded well to other treatments and for early-stage breast cancer to reduce the chances of it coming back.

### Dosage
Ado-trastuzumab emtansine is administered intravenously (IV). The standard dose for both early and metastatic HER2-positive breast cancer is 3.6 mg/kg every three weeks.  The treatment continues until the disease progresses or unacceptable side effects occur (for metastatic disease) or for a total of 14 cycles in the absence of disease recurrence or unacceptable toxicity (for early-stage breast cancer). The maximum dose is 3.6 mg/kg.  Dosage adjustments may be necessary based on factors like liver and kidney function, and the severity of side effects such as low platelet counts, elevated liver enzymes, and decreased left ventricular ejection fraction (LVEF). Specific dosage reduction guidelines are detailed in the prescribing information and should be followed closely by healthcare professionals.  This is not a medication to be self-administered. Pediatric dosage has not been established.

### Side Effects
Common side effects (>10% incidence) include:

* Fatigue
* Headache
* Peripheral neuropathy (numbness or tingling in the extremities)
* Nausea
* Constipation
* Diarrhea
* Vomiting
* Abdominal pain
* Skin rash
* Thrombocytopenia (low platelet count)
* Anemia
* Elevated liver enzymes
* Musculoskeletal pain
* Arthralgia (joint pain)
* Asthenia (weakness)
* Myalgia (muscle pain)
* Cough
* Dyspnea (shortness of breath)
* Fever

Less common but serious side effects include:

* Severe hepatotoxicity (liver damage), potentially leading to liver failure and death
* Cardiotoxicity (heart damage), including decreased LVEF
* Pulmonary toxicity (lung damage), including interstitial lung disease and pneumonitis
* Hemorrhage (bleeding)
* Severe neutropenia (low white blood cell count)
* Infusion reactions
* Hypersensitivity reactions
* Nodular regenerative hyperplasia (liver disease)


If any adverse effects occur, it's crucial to consult a healthcare professional immediately.


### How it Works
Ado-trastuzumab emtansine is a type of antibody-drug conjugate (ADC). It combines an antibody that targets the HER2 protein (trastuzumab) with a potent chemotherapy drug (DM1, a maytansine derivative).  The antibody acts like a "guided missile," delivering the chemotherapy directly to cancer cells that overexpress HER2.  Once inside the cancer cell, DM1 disrupts the microtubules, essential structures within cells that play a role in cell division and growth. This disruption leads to cell cycle arrest and ultimately, cell death (apoptosis).  Essentially, it targets and destroys HER2-positive cancer cells while minimizing damage to healthy cells.


### Precautions
* **Hypersensitivity:**  Ado-trastuzumab emtansine is contraindicated in patients with hypersensitivity to it or any of its components.
* **Hepatotoxicity:**  Close monitoring of liver function is essential.  Dose reduction or discontinuation may be necessary if liver enzyme levels rise significantly.
* **Cardiotoxicity:**  Regular monitoring of left ventricular function (LVEF) is crucial, as ado-trastuzumab emtansine can impair heart function.
* **Pregnancy:**  Ado-trastuzumab emtansine can harm the developing fetus.  Effective contraception is necessary for both men and women during treatment.
* **Drug Interactions:**  Strong CYP3A4 inhibitors may increase the levels of the active metabolite of ado-trastuzumab emtansine, potentially increasing toxicity.  Careful monitoring is needed if used with these inhibitors.  The use of anthracyclines (another type of chemotherapy drug) should be avoided for at least 7 months after stopping ado-trastuzumab emtansine due to the increased risk of cardiotoxicity.
* **Other Precautions:**  Patients with impaired liver or kidney function require careful monitoring and potential dosage adjustments.


### FAQs
* **Q: How is Ado-trastuzumab emtansine administered?**
    *A: It's administered intravenously (IV) over a specified infusion time, typically 90 minutes for the first dose, and 30 minutes for subsequent doses (if the first was tolerated).

* **Q: How long does treatment typically last?**
    *A:  For metastatic breast cancer, treatment continues until disease progression or unacceptable side effects.  For early-stage breast cancer, the standard duration is 14 cycles.

* **Q: What should I do if I miss a dose?**
    *A: Contact your healthcare provider immediately.  Do not attempt to adjust the schedule yourself.

* **Q: How should Ado-trastuzumab emtansine be stored?**
    *A: Follow the storage instructions provided by your pharmacist or healthcare provider.

* **Q: Are there any specific dietary restrictions while on this medication?**
    *A:  Generally, no specific dietary restrictions are associated with Ado-trastuzumab emtansine, but maintaining a healthy diet can support overall well-being during treatment.  It's always best to consult with your healthcare provider or a registered dietitian if you have concerns about diet and nutrition during treatment.

* **Q: Can I drive while taking this medication?**
    *A:  This depends on individual side effects, including fatigue or neurological symptoms.  Always follow your healthcare professional's advice and do not drive if you feel unwell or experience significant side effects.

**Disclaimer:** *This information is intended for educational purposes only and should not be considered medical advice.  Always consult your healthcare professional for accurate information regarding your specific medical condition and treatment plan.*
